Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Adds FedMed to PPOs Covering BrevaGen

NEW YORK (GenomeWeb News) – Genetic Technologies today said that its wholly owned subsidiary Phenogen Sciences has executed an agreement with preferred provider organization FedMed for access to its network of clinicians and healthcare providers.

The deal is the seventh between GTG and a US PPO, the Australian developer of the BrevaGen breast cancer risk assessment test, said. Last month, it signed agreements with MultiPlan and the Three Rivers Provider Network, and in total, the number of covered lives with access to BrevaGen as an in-network service is more than 102 million, GTG said.

Based in Rockville, Md., FedMed covers more than 40 million lives and has a network of more than 550,000 physicians, 60,000 ancillary care providers, and 4,000 hospitals nationwide. Phenogen is based in Charlotte, NC.

Financial and other terms of the deal were not disclosed.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.